VTGN (Vistagen Therapeutics) Other Current Liabilities: $0.32 Mil (As of Mar. 2026)


VTGN Vistagen Therapeutics Inc VTGN
29 GF Score
Price $0.24
GF Value $2.20
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Vistagen Therapeutics Other Current Liabilities?

Vistagen Therapeutics VTGN -1.25% 29 Other Current Liabilities is $0.32 Mil as of Mar. 2026. GuruFocus rates VTGN with a GF Score™ of 29/100 and a GF Value™ of $2.20 (Possible Value Trap). The stock has 3 warning signs investors should review.

Vistagen Therapeutics's other current liabilities for the quarter that ended in Mar. 2026 was $0.32 Mil.

Vistagen Therapeutics's quarterly other current liabilities declined from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($-0.00 Mil) but then increased from Dec. 2025 ($-0.00 Mil) to Mar. 2026 ($0.32 Mil).

Vistagen Therapeutics's annual other current liabilities increased from Mar. 2024 ($1.62 Mil) to Mar. 2025 ($3.36 Mil) but then declined from Mar. 2025 ($3.36 Mil) to Mar. 2026 ($0.32 Mil).

Vistagen Therapeutics Other Current Liabilities Related Terms

Vistagen Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Vistagen Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistagen Therapeutics Other Current Liabilities Chart

Vistagen Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.34 1.62 3.36 0.32

Vistagen Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.36 0.00 0.00 -0.00 0.32
VTGN
29GF Score
Vistagen Therapeutics Inc VTGN
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vistagen Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $0.32 Mil mean?
Vistagen Therapeutics (VTGN) has a Other Current Liabilities of $0.32 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Vistagen Therapeutics.
Is Vistagen Therapeutics' Other Current Liabilities too high?
Vistagen Therapeutics' current Other Current Liabilities is $0.32 Mil. Overall, Vistagen Therapeutics has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vistagen Therapeutics' Other Current Liabilities compare to PSTV and KYNB?
Vistagen Therapeutics' Other Current Liabilities of $0.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Vistagen Therapeutics. Vistagen Therapeutics's current Other Current Liabilities is $0.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistagen Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Vistagen Therapeutics (VTGN) is currently considered Possible Value Trap. The stock's GF Value™ is $2.20, compared to a current price of $0.24 — trading 88.9% below its estimated fair value. The current Other Current Liabilities is $0.32 Mil. Vistagen Therapeutics' overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Vistagen Therapeutics (VTGN), the current Other Current Liabilities is $0.32 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vistagen Therapeutics (VTGN) Overvalued in 2026?

Based on GuruFocus' analysis, Vistagen Therapeutics stock appears to be undervalued. The current stock price of $0.24 is trading 88.9% below its estimated GF Value™ of $2.20. GuruFocus considers Vistagen Therapeutics to be Possible Value Trap.

Key valuation signals for VTGN:

  • Other Current Liabilities: $0.32 Mil
  • GF Value™: $2.20 vs. price of $0.24 (88.9% below fair value)
  • GF Score™: 29/100 with 3 warning signs

No single metric tells the full story. See the VTGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vistagen Therapeutics Business Description

Address 343 Allerton Avenue, South San Francisco, CA, USA, 94080
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
29GF Score

Get the complete analysis for VTGN

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.24
Price
$2.20
GF Value